Therapeutics News and Research

RSS

UWM neuroscientist explores how estrogens regulate memory and brain function

Karyn Frick likes to think big. In college, she spent the summer after her junior year studying the neurobiology of memory in a lab at Johns Hopkins University. For hours at a time, Frick would watch rats scurry through mazes, entranced by their behavior.

22 Jul 2026

AI-powered PeptiVerse could accelerate peptide drug discovery

Penn Engineers have developed PeptiVerse, an AI-powered platform that predicts key chemical and biological properties of peptides, the strings of amino acids whose medical potential has been demonstrated by the success of GLP-1 drugs, the widely used weight-loss treatments.

21 Jul 2026

City of Hope launches trial to map how tumors change during immunotherapy resistance

City of Hope®, one of the largest and most advanced cancer research and treatment organizations in the United States with its National Medical Center ranked among the nation's top cancer centers by U.S. News & World Report, has opened an innovative Phase 2 clinical trial designed to map how tumors change as they begin to resist immunotherapy, treatment that improves the immune system's ability to fight disease.

21 Jul 2026

Mount Sinai establishes new autoimmunity center with $5 million gift

A $5 million gift from philanthropists Judith and Stewart Colton will establish a Colton Center for Autoimmunity within the Marc and Jennifer Lipschultz Precision Immunology Institute (PrIISM) at the Icahn School of Medicine at Mount Sinai.

21 Jul 2026

Tailored gene therapy dramatically reduces childhood epilepsy seizures in trial

SCN2A‑related developmental epileptic encephalopathy (DEE) is a rare, severe form of childhood epilepsy and one of the most common causes of monogenic autism.

21 Jul 2026

Thymus hormone identified as key player in reversing age-related inflammation

Chronic, low-grade inflammation in the body-a phenomenon known as "inflammaging" because it increases with age-has been linked to many of today's leading causes of illness and death, including cancer, heart disease, metabolic conditions and neurodegenerative diseases.

21 Jul 2026

Fairjourney Bio announces scientific program and leadership for The Antibody Series 2026

FairJourney Bio ("FJBio"), a global antibody discovery expert, has announced the program for The Antibody Series (TAS) 2026, which will explore how insights from natural antibody repertoires, advances in computational design, and novel engineering strategies are transforming the discovery and development of antibody therapeutics.

From FairJourney Biologics 21 Jul 2026

WHO Member States advance Pathogen Access and Benefit Sharing annex negotiations

WHO Member States have advanced negotiations on the Pathogen Access and Benefit Sharing (PABS) annex, a central component of the WHO Pandemic Agreement, while agreeing that continued discussions are needed to finalize a framework that supports a faster, more effective and equitable response to future pandemics.

21 Jul 2026

Missing ancestry data in single-cell atlases threatens fair medicine

The single-cell "atlases" that are increasingly used to map the human body and as training data for artificial intelligence models, may not represent the world's populations fairly, according to a study led by researchers at the Icahn School of Medicine at Mount Sinai.

20 Jul 2026

Daily polypill significantly improves cardiac function in heart failure patients

Treatment with a "polypill" that combines multiple medications into a single daily dose significantly enhanced cardiac function and reduced hospitalizations for patients with heart failure, according to a study led by Michigan Medicine and UT Southwestern Medical Center.

20 Jul 2026

ddPCR and NGS for viral surveillance in antiviral drug development

hVIVO explains how ddPCR and NGS support viral surveillance in antiviral trials, from detection and quantification to resistance sequencing.

From hVIVO 20 Jul 2026

Study identifies new waste clearance system in the eye

Many of the world's leading causes of irreversible blindness, including glaucoma and age-related macular degeneration, share a common problem: the buildup of fluid, waste and inflammatory debris in the back of the eye.

17 Jul 2026

Tau buildup in progressive supranuclear palsy alters brain networks linked to thinking and behavior

Researchers at Japan's National Institutes for Quantum Science and Technology (QST) have found that tau buildup in progressive supranuclear palsy (PSP) may affect brain networks involved in thinking and behavior.

17 Jul 2026

Study reveals mechanism underlying HBV-induced liver inflammation

Chronic hepatitis B virus (HBV) infection remains a major cause of global liver morbidity, leading to progressive necroinflammation that often culminates in cirrhosis and hepatocellular carcinoma.

17 Jul 2026

New battery-powered device detects Bundibugyo Ebola virus in thirty minutes

Professor Yasutoshi Kido of the Graduate School of Medicine, Osaka Metropolitan University (OMU), in collaboration with K.K. DNAFORM and the National Institute for Biomedical Research (INRB) of the Democratic Republic of the Congo, is developing a portable rapid diagnostic system for Ebola virus disease (EVD) caused by Bundibugyo virus (BDBV).

17 Jul 2026

LIG1 loss reveals new treatment strategy for aggressive breast cancer

Loss of one copy of the DNA Ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage.

16 Jul 2026

Immune pathway may promote the progression of oral precancerous lesions

Researchers at The University of Texas MD Anderson Cancer Center identified an immune pathway that may promote the progression of oral precancerous lesions into head and neck squamous cell carcinoma.

16 Jul 2026

Specialized dendritic cells found to coordinate antitumor immunity

Researchers at the Icahn School of Medicine at Mount Sinai have identified the immune cell that acts as the architect and coordinator of powerful immune hubs that form inside tumors and plays a key role in antitumor immunity.

16 Jul 2026

Fractyl Health reports positive randomized data from REMAIN-1 Midpoint Cohort demonstrating durable weight maintenance one year after GLP-1 discontinuation

Fractyl Health, Inc. (Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced positive one-year results from its REMAIN-1 Midpoint Cohort (“Midpoint Cohort”).

16 Jul 2026